10

15

20

25

30

35

## CLAIMS

1. A peptide having a cyclic structure and having an activity to restore the DNA-binding activity or the P53 protein-dependent transcription activity to mutant P53 protein, or a pharmaceutically acceptable salt thereof, said peptide being represented by general formula (I):

 $R^{1}(X^{1})^{n1}(X^{2})^{n2}(X^{3})^{n3}(X^{4})^{n4}(X^{5})^{n5}(X^{6})^{n6}(X^{7})^{n7}(X^{8})^{n8}(X^{9})^{n9}(X^{10})^{n10}(X^{11})^{n11}(X^{12})^{n12}(X^{13})^{n13}(X^{14})^{n14}(X^{15})^{n15}(X^{16})^{n16}(X^{17})^{n17}R^{2}$ (I)

{wherein any of  $X^1$  to  $X^{17}$  and n/1 to n17 may be denoted by  $X^1$ and ni, respectively (i stands for an integer of 1 to 17); Xi represents an amino acid residue or an organic acid residue as defined below; ni represents 0 or 1;  $(X^i)^{ni}$  represents  $X^i$ when ni is 1, and represents a bond when ni is 0; 7 to 17 different Xis (ni=1) are selected, arranged in order of increasing number i, and bonded to one another, with R1 bonded to the N-terminus and R<sup>2</sup> bonded to the C-terminus, to represent one sequence, in which a functional group in residue Xp (p is an integer of 1 to 11)  $\frac{1}{2}$ s selected from the group of  $X^1$  to  $X^{11}$ and a functional group/in residue Xq (q is an integer of 8 to 17, provided that q is larger than p) is selected from the group of X<sup>8</sup> to X<sup>17</sup> form a cyclic structure; R<sup>1</sup> represents substituted or unsubstituted alkanoyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aralkyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted aroyl, 9fluorenylmethoxycarbonyl, or hydrogen; X1 represents a residue of 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid, suberic acid, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic

30

35

acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3diaminopropionic acid, p-aminophenyla/lanine, serine, threonine, homoserine,  $\alpha$ -methylserine, 3-hydroxyproline or 4-hydroxyproline; X2 represents a residue of leucine, isoleucine, valine, alanine, norvaline, norleucine, 2-5 aminobutanoic acid, homoleucine,  $\beta$ -alanine,  $\alpha$ aminoisobutanoic acid,  $\beta$ -cyclopropylalanine,  $\beta$ chloroalanine, 1-aminocyclopenta/ne-1-carboxylic acid, 1amino-1-cyclohexanecarboxylic acid, 2-amino-1-10 cyclopentanecarboxylic acid, t/butylglycine, diethylglycine, t-butylalaniné, O-methylserine, cyclohexylglycine, cyclohexyl/alanine or glycine; x3 represents a residue of lysine, arginine, ornithine, 2,4diaminobutanoic acid, 2,3-diaminopropionic acid, p-15 aminophenylalanine or glycine; X4 represents a residue of serine, threonine, homoserine,  $\alpha$ -methylserine, 3hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, is oglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic 20 acid, 2,3-diaminopropionic acid, p-aminophenylalanine, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid; X<sup>5</sup> represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine; X6 represents a residue of lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic/acid, p-aminophenylalanine or glycine;  $X^7$  represents a residue of alanine,  $\beta$ -alanine, 2-aminobenzoic acid, 3-aminobenzoic acid, 4-aminobenzoic acid, 3aminomethylbenzoic acid, proline, 3-hydroxyproline, 4hydroxyproline, L-1,2,3,4-tetrahydroisoguinoline-7carboxylic acid, cysteine, homocysteine, penicillamine, 2,3-diaminopropionic acid, 2,4-diaminobutanoic acid, ornithine, lysine, p-aminophenylalanine, aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-

aminoadipic acid, 2-aminosuberic acid or glycine; X8 represents a residue of glutamine, asparagine, cysteine, homocysteine, penicillamine, aspartic/acid, glutamic acid, homoglutamic acid, isoaspartic acid, /isoglutamic acid, 2-5 aminoadipic acid, 2-aminosuberic aci/d, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, paminophenylalanine, serine, threomine, homoserine,  $\alpha$ methylserine, 3-hydroxyproline, 4-hydroxyproline, glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4mercaptobutanoic acid, mercaptoacetic acid, adipic acid or 10 suberic acid; X9 represents a residue of serine, threonine, homoserine,  $\alpha$ -methylserine, 3-hydroxyproline, 4hydroxyproline, cysteine, hømocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic 15 acid, isoglutamic acid, 2/aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, /2,4-diaminobutanoic acid, 2,3diaminopropionic acid, p-aminophenylalanine, glycine, 2mercaptobenzoic acid, 3/-mercaptopropionic acid, 4mercaptobutanoic acid, mercaptoacetic acid, adipic acid or 20 suberic acid; X10 represents a residue of serine, threonine, homoserine,  $\alpha$ -methyl $\phi$ erine, hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, /isoaspartic acid, isoglutamic acid, 2aminoadipic acid, /2-aminosuberic acid, ornithine, lysine, 25 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, paminophenylalanine, glycine, 2-mercaptobenzoic acid, 3mercaptopropioni¢ acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or suberic acid; X11 represents a residue of serine, threonine, homoserine,  $\alpha$ -30 methylserine, hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine, 35 glycine, 2-mercaptobenzoic acid, 3-mercaptopropionic acid, 4-mercaptobutanoic acid, mercaptoacetic acid, adipic acid or

suberic acid; X12 represents a residue of \( \frac{1}{2} \) ysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine; X13 represents a residue of histidine, alanine, 4-thiazolylalanine, 2thienylalanine, 2-pyridylalanine, 3-py/ridylalanine, 4-5 pyridylalanine, (3-N-methyl)piperidylalanine, 3-(2quinoyl)alanine, serine, threonine, homoserine, αmethylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine, homocysteine, penicillamine, aspartic acid, glutamic acid, 10 homoglutamic acid, isoaspartic acid, isoglutamic acid, 2aminoadipic acid, 2-aminosuberic acid, ornithine, lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, paminophenylalanine or glycine; X14 represents a residue of lysine, arginine, ornithine, 2/4-diaminobutanoic acid, 2,3-diaminopropionic acid, p/aminophenylalanine, serine, 15 threonine, homoserine,  $\alpha$ -methylserine, 3-hydroxyproline, 4-hydroxyproline, cysteine/homocysteine, penicillamine, aspartic acid, glutamic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2/aminoadipic acid, 2-aminosuberic 20 acid or glycine, and an amino group or guanidino group in the side chain of  $X^{14}$  may be modified with  $R^3$  ( $R^3$  has the same significance as R1); X15 represents lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, p-aminophenylalanine or glycine; X16 represents a 25 residue of leucine, alanine, 4-thiazolylalanine, 2thienylalanine, isoleucine, norleucine, homoleucine, valine, norvaline,  $\beta$ -alanine,  $\alpha$ -aminoisobutanoic acid, 2aminobutanoic acid,  $\beta$ -cyclopropylalanine,  $\beta$ -chloroalanine, 1-aminocyclopentane-1-carboxylic acid, 1-amino-1-30 cyclohexanecarboxy/lic acid, 2-amino-1cyclopentanecarboxylic acid, t-butylglycine, diethylglycine, t-butylalanine, O-methylserine, cyclohexylglyciné, cyclohexylalanine or glycine; X17 represents a residue of 2-mercaptoaniline, cysteamine, homocysteamine, cysteine, homocysteine, penicillamine,

ornithine, lysine, 2,3-diaminopropionic acid, 2,4-

diaminobutanoic acid, p-aminophenylalani/ne, glutamic acid, aspartic acid, homoglutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid or/2-aminosuberic acid; R<sup>2</sup> represents substituted or unsubstituted alkoxy, substituted or unsubstituted aralkyloky, amino, substituted 5 or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, or hydroxy; and one to several residues which are the same or different and arbitrarily selected from the group consisting of organic acid 10 residues, amino acid residues and a 12-aminododecanoic acid residue mentioned in the above Xi representations may be deleted, substituted or added at arbitrary positions in the sequence }.

15

20

35

- 2. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 1, wherein said cyclic structure is formed by a 3-S, S-CH<sub>2</sub>-S, S-CH<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-S, S-CH<sub>2</sub>-CO, CO-NH, NH-CO, O-CO or CO-O bond between  $X^p$  and  $X^q$ .
- 3. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 2, wherein X<sup>p</sup> (np=1) is an N-terminal residue and X<sup>q</sup> (nq=1) is a C-terminal residue.
- 4. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 2, wherein X<sup>p</sup> (np=1) is not an N-terminal residue and X<sup>q</sup> (nq=1) is not a C-terminal residue.
  - 5. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 2, wherein X<sup>p</sup> (np=1) is not an N-terminal residue and X<sup>q</sup> (nq=1) is a C-terminal residue.

- 6. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 2, wherein  $X^p$  (np=1) is an N-terminal residue and  $X^q$  (nq=1) is not a C-terminal residue.
- 7. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 3, wherein  $X^p$  (np=1) is  $X^1$  and  $X^q$  (nq=1) is  $X^{17}$ .
- 10 8. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 6, wherein X<sup>p</sup> (np=1) is X<sup>1</sup> and X<sup>q</sup> (nq=1) is X<sup>17</sup>.
- 9. A peptide having a cyclic structure or a
  15 pharmaceutically acceptable salt thereof according to claim
  3, wherein X<sup>p</sup> (np=1) is X<sup>f</sup> and X<sup>q</sup> (nq=1) is X<sup>16</sup>.
- 10. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 20 6, wherein X<sup>p</sup> (np=1) is an N-terminal residue and X<sup>q</sup> (nq=1) is X<sup>8</sup>.
- 11. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 25 4, wherein X<sup>p</sup> (np=1) is X<sup>8</sup> and X<sup>q</sup> (nq=1) is X<sup>14</sup>.
  - 12. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 5, wherein  $X^p$  (np=1) is  $X^3$  and  $X^q$  (nq=1) is a C-terminal residue.
  - 13. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 4, wherein  $X^p$  (np=1) is  $X^3$  and  $X^q$  (nq=1) is not a C-terminal residue.

35

30

10

15

20

25

- 14. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 6, wherein  $X^p$  (np=1) is an N-terminal residue and  $X^q$  (nq=1) is  $X^{11}$ .
- 15. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 1, said peptide having an amino acid sequence shown by one of SEQ ID NOS: 4-7 and 16-32 in which one to several residues which are the same or different and arbitrarily selected from the group consisting of organic acid residue, amino acid residues and a 12-aminododecanoic acid residue mentioned in the X<sup>i</sup> representations in claim 1 may be deleted, substituted or added.
- 16. A peptide having a cyclic structure or a pharmaceutically acceptable salt thereof according to claim 15, said peptide having an amino acid sequence shown by one of SEQ ID NOS: 4-7, 16, 19 and 25-32 in which one to several residues which are the same or different and arbitrarily selected from the group consisting of organic acid residues, amino acid residues and a 12-aminododecanoic acid residue mentioned in the Xi representations in claim 1 may be deleted, substituted or added.